Format

Send to

Choose Destination
Prev Med. 2017 Dec;105:372-377. doi: 10.1016/j.ypmed.2017.08.006.

Primary HPV testing recommendations of US providers, 2015.

Author information

1
Soltera Center for Cancer Prevention and Control, Tucson, AZ 85704, United States.
2
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States. Electronic address: msaraiya@cdc.gov.

Abstract

OBJECTIVE:

To investigate the HPV testing recommendations of US physicians who perform cervical cancer screening.

METHODS:

Data from the 2015 DocStyles survey of U.S. health care providers were analyzed using multivariate logistic regression to identify provider characteristics associated with routine recommendation of primary HPV testing for average-risk, asymptomatic women ≥30years old. The analysis was limited to primary care physicians and obstetrician-gynecologists who performed cervical cancer screening (N=843).

RESULTS:

Primary HPV testing for average-risk, asymptomatic women ≥30years old was recommended by 40.8% of physicians who performed cervical cancer screening, and 90.1% of these providers recommended primary HPV testing for women of all ages. The screening intervals most commonly recommended for primary HPV testing with average-risk, asymptomatic women ≥30years old were every 3years (35.5%) and annually (30.2%). Physicians who reported that patient HPV vaccination status influenced their cervical cancer screening practices were almost four times more likely to recommend primary HPV testing for average-risk, asymptomatic women ≥30years old than other providers (Adj OR=3.96, 95% CI=2.82-5.57).

CONCLUSION:

Many US physicians recommended primary HPV testing for women of all ages, contrary to guidelines which limit this screening approach to women ≥25years old. The association between provider recommendation of primary HPV testing and patient HPV vaccination status may be due to anticipated reductions in the most oncogenic HPV types among vaccinated women.

KEYWORDS:

Cervical cancer screening; HPV testing; Providers; United States

PMID:
29056319
PMCID:
PMC5809311
DOI:
10.1016/j.ypmed.2017.08.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center